{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:24:56Z","timestamp":1764174296615,"version":"3.38.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T00:00:00Z","timestamp":1477353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p> Neuroendocrine tumours are increasing in incidence and cause a variety of symptoms. The mammalian target of rapamycin (mTOR) pathway plays a key role in neuroendocrine tumour (NET) pathogenesis, leading to increased lipid synthesis, protein synthesis and cellular growth. Upregulation of this pathway is noted in both hereditary and sporadic NETs. This understanding has led to investigations of mTOR inhibitors as therapy for metastatic NETs. After promising preclinical findings, everolimus, an mTOR inhibitor, was trialled in the RADIANT-1\u22124 studies on patients with advanced, well differentiated NETs. RADIANT-3 and RADIANT-4 established the efficacy of everolimus in improving progression-free survival (PFS) for metastatic NET of pancreatic, lung and gastrointestinal origin, leading to the US Food and Drug Administration (FDA) approval for its use in tumour control in those settings. Everolimus treatment is generally well tolerated; common adverse events include stomatitis, diarrhoea, rash and hyperglycaemia. Although discontinuation rates are low, many patients may require dose modification to successfully continue therapy. The combination of everolimus with somatostatin analogues (SSAs) (such as octreotide or pasireotide) or other targeted agents such as bevacizumab has not produced additional incremental benefit, and dual biologic therapy is not used widely. Ongoing trials are investigating everolimus compared with chemotherapy, optimal sequencing of therapy and combination of everolimus with radiotherapy. Future research should concentrate on identification of predictive biomarkers for benefit from mTOR therapy and include quality of life as a measure. <\/jats:p>","DOI":"10.1177\/1756283x16674660","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T01:20:22Z","timestamp":1477444822000},"page":"132-141","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":33,"title":["Everolimus in the management of metastatic neuroendocrine tumours"],"prefix":"10.1177","volume":"10","author":[{"given":"David L.","family":"Chan","sequence":"first","affiliation":[{"name":"Odette Cancer Centre, Toronto, ON, Canada"}]},{"given":"Eva","family":"Segelov","sequence":"additional","affiliation":[{"name":"St Vincent\u2019s Hospital, New South Wales, Australia"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[{"name":"Odette Cancer Centre, 2075 Bayview Avenue, Room T2 047, Toronto, ON, Canada M4N 3M5"}]}],"member":"179","published-online":{"date-parts":[[2016,10,25]]},"reference":[{"key":"bibr1-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653"},{"key":"bibr2-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316158"},{"key":"bibr3-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4"},{"key":"bibr4-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1999.4683"},{"key":"bibr5-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603419"},{"key":"bibr6-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022171"},{"key":"bibr7-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.142"},{"key":"bibr8-1756283X16674660","first-page":"104","volume-title":"Presented at 2016 ENETS. Abstr #P1","volume":"103","author":"Fazio N.","year":"2016"},{"key":"bibr9-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29099"},{"key":"bibr10-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.23.14424"},{"key":"bibr11-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2082"},{"key":"bibr12-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200609"},{"key":"bibr13-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0503224102"},{"key":"bibr14-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ec124e"},{"key":"bibr15-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0806740"},{"key":"bibr16-1756283X16674660","first-page":"131","volume-title":"Presented at the 12th Annual ENETS conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona","volume":"102","author":"Kulke M.","year":"2015"},{"key":"bibr17-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.4005"},{"key":"bibr18-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.017"},{"key":"bibr19-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.5988"},{"key":"bibr20-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202203260804"},{"key":"bibr21-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-07-0202"},{"key":"bibr22-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"bibr23-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61742-X"},{"key":"bibr24-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.e15657"},{"key":"bibr25-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1159\/000443167"},{"journal-title":"Safety and Quality-Of-Life (QOL) assessments in the open-label, multicenter, phase IIIb, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET)","year":"2013","author":"Pavel M.","key":"bibr26-1756283X16674660"},{"key":"bibr27-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.6946"},{"key":"bibr28-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-10-0157"},{"key":"bibr29-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510"},{"issue":"1","key":"bibr30-1756283X16674660","first-page":"85","volume":"103","author":"Singh S.","year":"2016","journal-title":"Neuroendocrinology"},{"key":"bibr31-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.4093"},{"key":"bibr32-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.4090"},{"key":"bibr33-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181f94cc4"},{"key":"bibr34-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000219703.39149.85"},{"key":"bibr35-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S84177"},{"key":"bibr36-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00817-X"},{"key":"bibr37-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"bibr38-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.2669"},{"key":"bibr39-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"bibr40-1756283X16674660","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-10-0097"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X16674660","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756283X16674660","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X16674660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T02:03:40Z","timestamp":1740794620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756283X16674660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,25]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1177\/1756283X16674660"],"URL":"https:\/\/doi.org\/10.1177\/1756283x16674660","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"type":"print","value":"1756-2848"},{"type":"electronic","value":"1756-2848"}],"subject":[],"published":{"date-parts":[[2016,10,25]]}}}